Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Multi-Arm (Basket) Trial Investigating the Safety and Efficacy of IO102-IO103 in Combination With Pembrolizumab, as First-Line Treatment for Patients With Metastatic NSCLC, SCCHN, or Metastatic mUBC

NCT05077709 is registered in ClinicalTrials.gov with IO Biotech as lead sponsor.

NCT NCT05077709
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05077709 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Multi-Arm (Basket) Trial Investigating the Safety and Efficacy of IO102-IO103 in Combination With Pembrolizumab, as First-Line Treatment for Patients With Metastatic NSCLC, SCCHN, or Metastatic mUBC
Lead sponsor
IO Biotech
Phase
Phase 2
Overall status
Completed
Start date
April 11, 2022
Completion date
February 8, 2026
Enrollment
63 (actual)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

head and neck squamous cell carcinoma, lung cancer non small cell, urothelial carcinoma bladder